Basis: Four-quarter operating cash flow / FMP quote market capitalization × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The operating cash flow yield is N/A as of 2026-10-06T16:46:45.599Z.
Calculation as of: 2026-10-06T16:46:45.599Z.
Quote observation: 2026-10-06T16:41:53.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: f1b6469add1457cabf137e6e5cfb012e486d3d2c84b47330ed8a9effb8bf14c7
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
OPERATING CASH FLOW YIELD
N/A
Market Cap
$63.14M
Operating Cash Flow Yield
14.93%
TTM Avg
19.10%
3Y Avg
19.10%
5Y Avg
6.56%
Market Cap
$65.02M
Operating Cash Flow Yield
N/A
TTM Avg
2.92%
3Y Avg
2.92%
5Y Avg
2.92%
Market Cap
$63.78M
Operating Cash Flow Yield
N/A
TTM Avg
3.39%
3Y Avg
3.39%
5Y Avg
3.39%
Market Cap
$64.39M
Operating Cash Flow Yield
N/A
TTM Avg
76.71%
3Y Avg
76.71%
5Y Avg
76.71%
Market Cap
$68.27M
Operating Cash Flow Yield
184.46%
TTM Avg
137.45%
3Y Avg
137.45%
5Y Avg
137.45%
| NAME | MARKET CAP | OPERATING CASH FLOW YIELD | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Cingulate Inc. (CING) | $65.33M | N/A | N/A | N/A | N/A |
| InterCure Ltd. (INCR)vs › | $63.14M | 14.93% | 19.10% | 19.10% | 6.56% |
| Gossamer Bio, Inc. (GOSS)vs › | $65.02M | N/A | 2.92% | 2.92% | 2.92% |
| RenovoRx, Inc. (RNXT)vs › | $64.65M | N/A | N/A | N/A | N/A |
| Pliant Therapeutics, Inc. (PLRX)vs › | $63.78M | N/A | 3.39% | 3.39% | 3.39% |
| Heron Therapeutics, Inc. (HRTX)vs › | $64.39M | N/A | 76.71% | 76.71% | 76.71% |
| Alps Group Inc (ALPS)vs › | $63.23M | N/A | N/A | N/A | N/A |
| Fortress Biotech, Inc. (FBIO)vs › | $68.27M | 184.46% | 137.45% | 137.45% | 137.45% |
| iBio, Inc. (IBIO)vs › | $68.81M | N/A | N/A | N/A | N/A |
| Kalaris Therapeutics Inc (KLRS)vs › | $61.77M | N/A | N/A | N/A | N/A |
OCF Yield = TTM Operating Cash Flow / Market Cap
Operating cash flow yield is the inverse of P/OCF, expressing trailing operating cash flow as a percentage of price. It sits between earnings yield (before non-cash accrual effects) and FCF yield (before capital expenditure).
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
